IMR Press / FBL / Volume 16 / Issue 7 / DOI: 10.2741/3864

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis
Show Less
1 Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium
Academic Editor:Arthur Chu
Front. Biosci. (Landmark Ed) 2011, 16(7), 2427–2450; https://doi.org/10.2741/3864
Published: 1 June 2011
(This article belongs to the Special Issue Blood coagulation, inflammation, and thrombosis)
Abstract

Since its discovery more than 20 years ago, a lot has been revealed about the biochemistry and physiological behaviour of carboxypeptidase U (CPU). Recent advances in CPU research include the unravelling of the crystal structure of proCPU and revealing the molecular mechanisms for the marked instability of the active enzyme, CPU. The recent development of two highly sensitive assays has cleared the path toward the direct measurement of CPU in circulation or the determination of CPU generation, rather than the measurement of total proCPU concentration in plasma. Finally, since CPU is known to have a prominent bridging function between coagulation and fibrinolysis, the development of CPU inhibitors as profibrinolytic agents is an attractive new concept and has gained a lot of interest from several research groups and from the pharmaceutical industry. These recent advances in CPU research are reviewed in this literature update.

Share
Back to top